ZVRA Valuation

Zevra Therapeutics Inc

Add to Watchlist

Advanced Chart

11.700

-0.32(-2.662%)1D

Overview
Forecast
Valuation
Earnings

ZVRA Relative Valuation

ZVRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZVRA is overvalued; if below, it's undervalued.

Historical Valuation

Zevra Therapeutics Inc (ZVRA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.08 is considered Undervalued compared with the five-year average of -6.73. The fair price of Zevra Therapeutics Inc (ZVRA) is between 1303.66 to 1326.95 according to relative valuation methord. Compared to the current price of 11.70 USD , Zevra Therapeutics Inc is Undervalued By 99.1%.

Relative Value

Fair Zone

1303.66-1326.95

Current Price：11.70

99.1%

Undervalued

7.51

Trailing

Forward

-114.66

EV/EBITDA

Zevra Therapeutics Inc. (ZVRA) has a current EV/EBITDA of -114.66. The 5-year average EV/EBITDA is -4.19. The thresholds are as follows: Strongly Undervalued below -61.35, Undervalued between -61.35 and -32.77, Fairly Valued between 24.39 and -32.77, Overvalued between 24.39 and 52.97, and Strongly Overvalued above 52.97. The current Forward EV/EBITDA of -114.66 falls within the Strongly Undervalued range.

2819.83

EV/EBIT

Zevra Therapeutics Inc. (ZVRA) has a current EV/EBIT of 2819.83. The 5-year average EV/EBIT is 1553.98. The thresholds are as follows: Strongly Undervalued below -33909.06, Undervalued between -33909.06 and -16177.54, Fairly Valued between 19285.50 and -16177.54, Overvalued between 19285.50 and 37017.02, and Strongly Overvalued above 37017.02. The current Forward EV/EBIT of 2819.83 falls within the Historic Trend Line -Fairly Valued range.

6.02

Zevra Therapeutics Inc. (ZVRA) has a current PS of 6.02. The 5-year average PS is 9.41. The thresholds are as follows: Strongly Undervalued below -5.71, Undervalued between -5.71 and 1.85, Fairly Valued between 16.97 and 1.85, Overvalued between 16.97 and 24.52, and Strongly Overvalued above 24.52. The current Forward PS of 6.02 falls within the Historic Trend Line -Fairly Valued range.

-32.82

P/OCF

Zevra Therapeutics Inc. (ZVRA) has a current P/OCF of -32.82. The 5-year average P/OCF is -4.36. The thresholds are as follows: Strongly Undervalued below -16.29, Undervalued between -16.29 and -10.32, Fairly Valued between 1.60 and -10.32, Overvalued between 1.60 and 7.56, and Strongly Overvalued above 7.56. The current Forward P/OCF of -32.82 falls within the Strongly Undervalued range.

108.04

P/FCF

Zevra Therapeutics Inc. (ZVRA) has a current P/FCF of 108.04. The 5-year average P/FCF is -3.35. The thresholds are as follows: Strongly Undervalued below -35.15, Undervalued between -35.15 and -19.25, Fairly Valued between 12.55 and -19.25, Overvalued between 12.55 and 28.45, and Strongly Overvalued above 28.45. The current Forward P/FCF of 108.04 falls within the Strongly Overvalued range.

Zevra Therapeutics Inc (ZVRA) has a current Price-to-Book (P/B) ratio of 16.02. Compared to its 3-year average P/B ratio of 5.22 , the current P/B ratio is approximately 207.05% higher. Relative to its 5-year average P/B ratio of 3.65, the current P/B ratio is about 338.73% higher. Zevra Therapeutics Inc (ZVRA) has a Forward Free Cash Flow (FCF) yield of approximately -9.32%. Compared to its 3-year average FCF yield of -13.60%, the current FCF yield is approximately -31.45% lower. Relative to its 5-year average FCF yield of -8.15% , the current FCF yield is about 14.33% lower.

15.62

P/B

Median3y

5.22

Median5y

3.65

-9.41

FCF Yield

Median3y

-13.60

Median5y

-8.15

Competitors Valuation Multiple

The average P/S ratio for ZVRA's competitors is 40.30, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA) exhibits a P/S ratio of 6.02, which is -85.06% above the industry average. Given its robust revenue growth of 495.65%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ZVRA.O

Zevra Therapeutics Inc

Arrivent Biopharma Inc

Loss

645.18M

ABUS.O

Arbutus Biopharma Corp

Gyre Therapeutics Inc

SIGA Technologies Inc

Amylyx Pharmaceuticals Inc

Loss

-100.00%

697.29M

Performance Decomposition

Market capitalization of ZVRA increased by 52.94% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.43M to 20.40M.

The secondary factor is the Margin Expansion, contributed -96.87%to the performance.

Overall, the performance of ZVRA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

495.65%

3.43M → 20.40M

Revenue Growth

-96.87%

-485.31 → -15.19

Margin Expansion

-345.84%

2.56 → -6.29

P/E Change

52.94%